Objective:

To explore the advancements and clinical implications of suprachoroidal drug delivery in ophthalmology, emphasizing its significance in improving treatment outcomes.

Key Findings:

• Suprachoroidal administration offers a good safety profile and potential for sustained drug delivery, with implications for various ocular conditions.
• The FDA approved Xipere for suprachoroidal use, marking a significant milestone in ocular therapeutics and paving the way for future innovations.
• Suprachoroidal injections achieve durable drug levels in targeted tissues while limiting anterior-segment exposure, addressing limitations of traditional delivery methods.

Interpretation:

The suprachoroidal route represents a paradigm shift in ocular drug delivery, addressing limitations of traditional methods and enhancing therapeutic efficacy, particularly for macular disorders.

Limitations:

• Further clinical studies are needed to fully establish long-term safety and efficacy, particularly in diverse patient populations.
• The technology may require specialized training for proper administration, which could limit widespread adoption.

Conclusion:

Suprachoroidal injections are poised to revolutionize ocular drug delivery, offering targeted treatment options with reduced systemic side effects, though challenges in training and implementation remain.